ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Spondylarthropathies"

  • Abstract Number: 0357 • ACR Convergence 2021

    Identifying Predictors of Unemployment in Axial Spondyloarthropathy: Data from the Ankylosing Spondylitis Registry of Ireland

    Sinead Maguire1, Wilson Fiona2, Phil Gallagher3 and Finbar (Barry) O'Shea1, 1St James's Hospital, Dublin, Ireland, 2Discipline of Physiotherapy, Trinity College Dublin, Dublin, Ireland, 3St Vincent's Hospital, Dublin, Ireland

    Background/Purpose: Axial spondyloarthropathy (axSpA) is an inflammatory arthritis of the axial skeleton. Persistent disease activity can result in significant disability and affect ability to maintain…
  • Abstract Number: 0562 • ACR Convergence 2021

    Inpatient Epidemiology and Resource Utilization of Ankylosing Spondylitis: National Inpatient Sample 2018

    Patompong Ungprasert1, Thanat Chaikijurajai2, Karn Wijarnpreecha3 and Paul Kroner3, 1Cleveland Clinic, Cleveland Heights, OH, 2Cleveland Clinic, Cleveland, OH, 3Mayo Clinic Florida, Jacksonville, FL

    Background/Purpose: Little is known about inpatient epidemiology, economic burden and resource utilization of patients with ankylosing spondylitis (AS). The current study aims to describe those…
  • Abstract Number: 0992 • ACR Convergence 2021

    Inflammatory Arthritis in HIV-Infected Humanized Mice

    Can Sungur1, Ayse Ozanturk1, Hongbo Gao1, Li-ping Yang1, Liang Shan1 and Wayne Yokoyama2, 1Washington University, St Louis, MO, 2Washington University School of Medicine, St. Louis, MO

    Background/Purpose: Human immunodeficiency virus (HIV) remains a significant life-threatening agent and burden on public health. Lesser studied and understood aspects of HIV include HIV-associated inflammatory…
  • Abstract Number: 1305 • ACR Convergence 2021

    Undiagnosed Depression in Axial Spondyloarthropathy and the Negative Impact on Patient Outcomes: Results of a Screening Study

    Sinead Maguire1, Phil Gallagher2 and Finbar (Barry) O'Shea1, 1St James's Hospital, Dublin, Ireland, 2St Vincent's Hospital, Dublin, Ireland

    Background/Purpose: Previous research in axial spondyloarthropathy(axSpA) has shown this population to have a high prevalence of depression. This co-morbidity has been previously shown to impact…
  • Abstract Number: 1329 • ACR Convergence 2021

    Guselkumab (TREMFYA®) Maintains Resolution of Dactylitis and Enthesitis in Patients with Active Psoriatic Arthritis: Results Through 2 Years from a Phase 3 Study

    Proton Rahman1, Iain McInnes2, Atul Deodhar3, Georg Schett4, Philip Mease5, May Shawi6, Daniel Cua7, Jonathan Sherlock8, Alexa Kollmeier9, Xie Xu7, Yusang Jiang7, Shihong Sheng7, Christopher Ritchlin10 and Dennis McGonagle11, 1Department of Medicine, Eastern Health and Memorial University of Newfoundland, St John's, NL, Canada, 2University of Glasgow, School of Medicine, Glasgow, Scotland, United Kingdom, 3Oregon Health & Science University, Portland, OR, 4Universitätsklinikum Erlangen, Department of Internal Medicine 3 – Rheumatology and Immunology, Erlangen, Germany, Erlangen, Germany, 5Swedish Medical Center/Providence St. Joseph Health and University of Washington, Seattle, WA, 6Janssen Immunology Global Commercial Strategy Organization, Toronto, ON, Canada, 7Janssen Research & Development, LLC, Spring House, PA, 8Janssen Research & Development, LLC and University of Oxford, Spring House, PA, 9Janssen Research & Development, LLC, La Jolla, CA, 10Division of Allergy, Immunology, and Rheumatology, School of Medicine and Dentistry, University of Rochester Medical Center, Rochester, NY, 11University of Leeds, Leeds, United Kingdom

    Background/Purpose: Guselkumab (GUS), a selective inhibitor of IL-23, significantly improved the diverse manifestations of active psoriatic arthritis (PsA), including dactylitis and enthesitis, in the DISCOVER…
  • Abstract Number: 1330 • ACR Convergence 2021

    Effect of Guselkumab (TREMFYA®), a Selective IL-23p19 Inhibitor, on Axial-Related Endpoints in Patients with Active PsA: Results from a Phase 3, Randomized, Double-blind, Placebo-controlled Study Through 2 Years

    Philip Mease1, Philip S Helliwell2, Dafna Gladman3, Denis Poddubnyy4, Xenofon Baraliakos5, Soumya Chakravarty6, Alexa Kollmeier7, Xie Xu8, Shihong Sheng8, Stephen Xu8, May Shawi9, Désirée van der Heijde10 and Atul Deodhar11, 1Swedish Medical Center/Providence St. Joseph Health and University of Washington, Seattle, WA, 2Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom, 3Schroeder Arthritis Institute, Krembil Research Institute, Toronto Western Hospital, Toronto, ON, Canada, 4Department of Rheumatology, Charité – Universitätsmedizin, Berlin, Germany, 5Rheumazentrum Ruhrgebiet Herne, Ruhr-Universität Bochum, Herne, Germany, 6Janssen Scientific Affairs, LLC and Drexel University College of Medicine, Horsham, PA, 7Janssen Research & Development, LLC, La Jolla, CA, 8Janssen Research & Development, LLC, Spring House, PA, 9Janssen Immunology Global Commercial Strategy Organization, Toronto, ON, Canada, 10Department of Rheumatology, Leiden University Medical Center, Meerssen, Netherlands, 11Oregon Health & Science University, Portland, OR

    Background/Purpose: Guselkumab (GUS), a selective IL-23p19 inhibitor, resulted in greater mean improvements in BASDAI scores vs placebo (PBO) at W24 among patients (pts) with active…
  • Abstract Number: 1331 • ACR Convergence 2021

    Guselkumab (TREMFYA®) Improves Anemia in Patients with Active Psoriatic Arthritis: Results from Two Phase 3 Randomized Controlled Clinical Trials

    Arthur Kavanaugh1, Yan Liu2, Proton Rahman3, Philip Mease4, Laure Gossec5, Xie Xu2, Elizabeth Hsia2, May Shawi6, Chenglong Han2, Marlies Neuhold7 and Atul Deodhar8, 1University of California San Diego, La Jolla, CA, 2Janssen Research & Development, LLC, Spring House, PA, 3Department of Medicine, Eastern Health and Memorial University of Newfoundland, St John's, NL, Canada, 4Swedish Medical Center/Providence St. Joseph Health and University of Washington, Seattle, WA, 5Sorbonne Université; APHP, Rheumatology Department, Pitié-Salpêtrière Hospital, Paris, France, 6Janssen Immunology Global Commercial Strategy Organization, Toronto, ON, Canada, 7Janssen-Cilag, Zug, Switzerland, 8Oregon Health & Science University, Portland, OR

    Background/Purpose: Anemia related to systemic inflammation can be an important feature of psoriatic arthritis (PsA). Hemoglobin (Hgb) levels have been shown to be inversely related…
  • Abstract Number: 1775 • ACR Convergence 2021

    Isolated Axial versus Concomitant Peripheral Disease in Psoriatic Arthritis

    Timothy Kwok1, Mitchell Sutton2, Richard Cook3, Daniel Pereira4 and Dafna Gladman5, 1Toronto Western Hospital, University Health Network, University of Toronto, Toronto, ON, Canada, 2Centre for Prognosis Studies in the Rheumatic Diseases, Krembil Research Institute, Toronto Western Hospital, University Health Network, Toronto, ON, Canada, 3Department of Statistics and Actuarial Sciences, University of Waterloo, Waterloo, ON, Canada, 4University Health Network, Toronto, ON, Canada, 5Schroeder Arthritis Institute, Krembil Research Institute, Toronto Western Hospital, Toronto, ON, Canada

    Background/Purpose: Isolated axial involvement exists in 2 to 5% of all psoriatic arthritis (PsA) patients. However, it is currently unknown whether patients with isolated axial…
  • Abstract Number: 1803 • ACR Convergence 2021

    Long-term Safety of Guselkumab (TREMFYA®) in Patients with Active Psoriatic Arthritis: Pooled Results from 3 Randomized Clinical Trials Through up to 2 Years

    Proton Rahman1, Christopher Ritchlin2, Philip Mease3, Philip S Helliwell4, Wolf-Henning Boehncke5, Iain McInnes6, May Shawi7, Anne Marilise Marrache8, Alexa Kollmeier9, Xie Xu10, Jenny Yu10, Yanli Wang10, Shihong Sheng10 and Alice Gottlieb11, 1Department of Medicine, Eastern Health and Memorial University of Newfoundland, St John's, NL, Canada, 2Division of Allergy, Immunology, and Rheumatology, School of Medicine and Dentistry, University of Rochester Medical Center, Rochester, NY, 3Swedish Medical Center/Providence St. Joseph Health and University of Washington, Seattle, WA, 4Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom, 5Geneva University Hospitals, Geneva, Switzerland, 6University of Glasgow, School of Medicine, Glasgow, Scotland, United Kingdom, 7Janssen Immunology Global Commercial Strategy Organization, Toronto, ON, Canada, 8Janssen Inc., Toronto, ON, Canada, 9Janssen Research & Development, LLC, La Jolla, CA, 10Janssen Research & Development, LLC, Spring House, PA, 11Icahn School of Medicine at Mount Sinai, New York, NY

    Background/Purpose: Guselkumab (GUS), a targeted IL-23 inhibitor, demonstrated significant improvements in signs and symptoms of psoriatic arthritis (PsA) and a favorable safety profile through week…
  • Abstract Number: 1804 • ACR Convergence 2021

    Targeted Safety Analyses of Guselkumab (TREMFYA®): Long-term Results from Randomized Clinical Trials in Patients with Active Psoriatic Arthritis and Moderate to Severe Psoriasis

    Philip Mease1, Peter Foley2, Kristian Reich3, Soumya Chakravarty4, May Shawi5, Ya-Wen Yang6, Megan Miller7, Alexa Kollmeier8, Xie Xu7, Jenny Yu7, Yanli Wang7, Shihong Sheng7, Yin You7 and Iain McInnes9, 1Swedish Medical Center/Providence St. Joseph Health and University of Washington, Seattle, WA, 2University of Melbourne, Carlton, Australia, 3University Medical Center Hamburg-Eppendorf, Hamburg, Germany, 4Janssen Scientific Affairs, LLC and Drexel University College of Medicine, Horsham, PA, 5Janssen Immunology Global Commercial Strategy Organization, Toronto, ON, Canada, 6Janssen Global Services, LLC, Horsham, PA, 7Janssen Research & Development, LLC, Spring House, PA, 8Janssen Research & Development, LLC, La Jolla, CA, 9University of Glasgow, School of Medicine, Glasgow, Scotland, United Kingdom

    Background/Purpose: Guselkumab (GUS), a human monoclonal antibody that specifically binds to the p19 subunit of IL-23, demonstrated efficacy and a favorable safety profile in active…
  • Abstract Number: 1806 • ACR Convergence 2021

    Designing a Phase 3b, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Investigate the Effect of Guselkumab (TREMFYA®/sup>) Dosing Interval in Psoriatic Arthritis Patients with Inadequate Response to Tumor Necrosis Factor Inhibition

    Alexis Ogdie-Beatty1, Joseph Merola2, Philip Mease3, Christopher Ritchlin4, Jose Scher5, Daphne Chan6, Soumya Chakravarty7, Wayne Langholff8, Olivia Choi9, Yevgeniy Krol9, Katelyn Rowland9 and Alice Gottlieb10, 1University of Pennsylvania, Philadelphia, PA, 2Harvard Medical School, Brigham and Women’s Hospital, Boston, MA, 3Swedish Medical Center/Providence St. Joseph Health and University of Washington, Seattle, WA, 4Division of Allergy, Immunology, and Rheumatology, School of Medicine and Dentistry, University of Rochester Medical Center, Rochester, NY, 5New York University School of Medicine, New York, NY, 6Janssen Scientific Affairs, LLC, Spring House, PA, 7Janssen Scientific Affairs, LLC and Drexel University College of Medicine, Horsham, PA, 8Janssen Research & Development, LLC, Spring House, PA, 9Janssen Scientific Affairs, LLC, Horsham, PA, 10Icahn School of Medicine at Mount Sinai, New York, NY

    Background/Purpose: Tumor necrosis factor inhibitors (TNFi) are frequently chosen as the first biologic therapy for patients (pts) with PsA, though a sizeable proportion of pts…
  • Abstract Number: 1919 • ACR Convergence 2021

    Detection of Radiographic Sacroiliitis with an Artificial Neural Network in Patients with Suspicion of Axial Spondyloarthritis

    Denis Poddubnyy1, Fabian Proft2, Kay-Geert Hermann2, Laura Spiller2, Stefan Niehues2, Lisa Adams2, Mikhail Protopopov2, Valeria Rios Rodriguez2, Burkhard Muche2, Judith Rademacher2, Murat Torgutalp2, Keno Bressem2 and Janis Vahldiek2, 1Department of Rheumatology, Charité – Universitätsmedizin, Berlin, Germany, 2Charité University Medicine Berlin, Berlin, Germany

    Background/Purpose: Conventional radiography of the sacroiliac joints is still recommended as the first imaging method for the diagnosis of axial spondyloarthritis (axial SpA). In many…
  • Abstract Number: 0058 • ACR Convergence 2020

    Drug Retention and Discontinuation of Biological DMARDs and Novel Small Molecules: Data from the Singapore National Biologics Registry

    Li Wearn Koh1, Man Hua Aw2, Preeti Dhanasekaran3, Rosa Lim Mui San1, Stephanie Wong4, Xanthe Chua5, Wei Joo Choy1, Manjari Lahiri6 and Siaw Ing Yeo2, 1Tan Tock Seng Hospital, Singapore, Singapore, 2Singapore General Hospital, Singapore, Singapore, 3National University of Singapore, Singapore, Singapore, 4Clinical Research and Innovation Office, Tan Tock Seng Hospital Singapore, Singapore, Singapore, 5Tan Tock Seng Hospital, Singapore, Singapore, Singapore, 6National University Hospital, Singapore, Singapore

    Background/Purpose: To describe drug retention rate and reasons for discontinuation of biological disease modifying anti-rheumatic drugs ( bDMARD) and novel small molecules in patients from…
  • Abstract Number: 1304 • ACR Convergence 2020

    Uveitis Occurrence in Early Inflammatory Back Pain: Five Years Data from a Prospective French Nationwide Cohort

    Daniel Wendling1, Clement Prati2, Thierry Lequerre3, Corinne Miceli-Richard4, Maxime Dougados5, Anna Molto6 and Xavier Guillot7, 1CHU Besançon, department of rheumatology, Besancon, France, 2Rheumatology, University Teaching Hospital, Besançon, France, 3Rheumatology, University Teaching Hospital, Rouen, France, 4Paris Descartes University, Department of Rheumatology - Hôpital Cochin, Assistance Publique - Hôpitaux de Paris, Paris, France, 5Department of Rheumatology, Hopital Cochin, Université de Paris, Paris, France, 6Rheumatology Department, Cochin Hospital, APHP, Paris, France, Paris, France, 7CHU Reunion, Saint Denis, Reunion

    Background/Purpose: Uveitis is the most frequent extra rheumatological manifestation in axial Spondyloarthritis (SpA). DESIR is a prospective multicenter cohort of patients with early inflammatory back…
  • Abstract Number: 1535 • ACR Convergence 2020

    Frequency and Anatomic Distribution of Magnetic Resonance Imaging Lesions in the Sacro-iliac Joints of Healthy Subjects and Patients with Spondyloarthritis

    Sophie Hecquet1, Jean-Philippe Lustig2, Frank Verhoeven1, Mickaël Chouk1, Sébastien Aubry2, Daniel Wendling3 and Clement Prati1, 1Rheumatology, University Teaching Hospital, Besançon, France, 2Radiology, University Teaching Hospital, Besançon, France, 3CHU Besançon, department of rheumatology, Besancon, France

    Background/Purpose: Lesions detected by magnetic resonance imaging (MRI) of the sacroiliac joints are critical to the diagnosis of non-radiographic axial spondyloarthritis. However, some lesions, such…
  • 1
  • 2
  • 3
  • …
  • 5
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology